163 related articles for article (PubMed ID: 15935395)
1. Rimonabant: the first therapeutically relevant cannabinoid antagonist.
Carai MA; Colombo G; Gessa GL
Life Sci; 2005 Sep; 77(19):2339-50. PubMed ID: 15935395
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
Carai MA; Colombo G; Maccioni P; Gessa GL
CNS Drug Rev; 2006; 12(2):91-9. PubMed ID: 16958983
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
5. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats.
Dyr W; Ligieza J; Kostowski W
Alcohol; 2008 Sep; 42(6):509-12. PubMed ID: 18504086
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
7. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
8. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
Maccioni P; Colombo G; Carai MA
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant--a selective CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
[TBL] [Abstract][Full Text] [Related]
10. Drug addiction.
Justinova Z; Panlilio LV; Goldberg SR
Curr Top Behav Neurosci; 2009; 1():309-46. PubMed ID: 21104390
[TBL] [Abstract][Full Text] [Related]
11. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
[TBL] [Abstract][Full Text] [Related]
12. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus.
Rorato R; Miyahara C; Antunes-Rodrigues J; Elias LL
Regul Pept; 2013 Mar; 182():12-8. PubMed ID: 23327999
[TBL] [Abstract][Full Text] [Related]
14. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant.
Gerdeman GL; Schechter JB; French ED
Neuropsychopharmacology; 2008 Oct; 33(11):2747-59. PubMed ID: 18059436
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
[TBL] [Abstract][Full Text] [Related]
17. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.
Colombo G; Agabio R; Diaz G; Lobina C; Reali R; Gessa GL
Life Sci; 1998; 63(8):PL113-7. PubMed ID: 9718088
[TBL] [Abstract][Full Text] [Related]
18. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.
Maccioni P; Pes D; Carai MA; Gessa GL; Colombo G
Behav Pharmacol; 2008 May; 19(3):197-209. PubMed ID: 18469537
[TBL] [Abstract][Full Text] [Related]
19. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
López-Moreno JA; González-Cuevas G; Navarro M
Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
[TBL] [Abstract][Full Text] [Related]
20. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats.
Mølhøj S; Hansen HS; Schweiger M; Zimmermann R; Johansen T; Malmlöf K
Eur J Pharmacol; 2010 Nov; 646(1-3):38-45. PubMed ID: 20727879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
